MabVax Therapeutics

Science         Innovation         Determination         Hope         Health  

  Mabvax Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative vaccine and monoclonal antibody-based therapeutics for the diagnosis and treatment of cancer.

     We generate our pipeline of antibody based product candidates from patients who have been vaccinated with the propriety vaccines we have licensed from Memorial Sloan-Kettering Cancer Center (MSKCC).  Our unique approach of surveying the protective immune response from many patients to identify the ideal monoclonal antibody candidate against a specific target on the surface of a cancer cell is a novel next-generation human antibody technology platform. 

    Our therapeutic vaccines were developed at Memorial Sloan-Kettering Cancer Center (MSKCC) and exclusively licensed to MabVax.  Our lead cancer vaccines targeting recurrent sarcoma and ovarian cancer are currently in proof of concept Phase II multi-center clinical trials.  A vaccine to address the orphan disease neuroblastoma has completed an initial Phase 1 trial at MSKCC yielding encouraging results.

MabVax Therapeutics Clinical Trials

MabVax Therapeutics In The News

Read our latest press release > READ MORE

 Events and Presentations > READ MORE

INVESTOR INFORMATION > READ MORE